Walleye Capital’s Madrigal Pharmaceuticals MDGL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$184K Buy
+366
New +$193K ﹤0.01% 4870
2026
Q2
– Sell
-13,227
Closed -$6.78M – 5011
2026
Q1
$6.92M Buy
13,227
+13,158
+19,070% +$6.29M 0.03% 597
2025
Q4
$40.2K Buy
+69
New +$35.2K ﹤0.01% 4131
2025
Q3
– Sell
-288
Closed -$107K – 4868
2025
Q2
$87.2K Buy
+288
New +$85.8K ﹤0.01% 3834
2024
Q3
– Sell
-58
Closed -$16.2K – 5646
2024
Q2
$16.2K Sell
58
-1,035
-95% -$246K ﹤0.01% 5152
2024
Q1
$292K Buy
+1,093
New +$258K ﹤0.01% 3685
2020
Q1
– Sell
-307
Closed -$28K – 1371
2019
Q4
$28K Buy
+307
New +$29.8K ﹤0.01% 1577

Other funds holding MDGL

Walleye Capital's MDGL Position: Q3 2026 in Review

Walleye Capital opened a new position in Madrigal Pharmaceuticals (MDGL) in Q3 2026: 366 shares worth $184K. The stake represents ﹤0.01% of the portfolio and ranks #4870 among its holdings. This is a return to the name: Walleye Capital previously reported a position in MDGL as recently as Q1 2026.

Walleye Capital first reported a position in MDGL in Q4 2019 and has held it in 7 quarters since. The position peaked at $6.92M in Q1 2026. 442 funds tracked by Wall St. Rank hold MDGL as of Q3 2026.

  • Walleye Capital held 366 shares of Madrigal Pharmaceuticals worth $184K as of Q3 2026.
  • Madrigal Pharmaceuticals was a new Walleye Capital position in Q3 2026.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Walleye Capital's portfolio in Q3 2026, its #4870 holding.
  • Walleye Capital first reported a position in Madrigal Pharmaceuticals in Q4 2019 and has held it in 7 quarters since.
  • Walleye Capital's Madrigal Pharmaceuticals position peaked at $6.92M in Q1 2026.
  • 442 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2026.

Based on Walleye Capital's 13F filing for Q3 2026, filed 13 Nov 2026.